ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.34 ▼ -11.70 (-4.25%)HPE: $70.10 ▼ -3.36 (-4.57%)AMD: $590.61 ▼ -17.49 (-2.88%)DELL: $574.44 ▼ -11.62 (-1.98%)PANW: $399.92 ▼ -18.86 (-4.50%)MRNA: $214.33 ▼ -10.67 (-4.74%)AAPL: $339.63 ▲ 2.99 (0.89%)AMZN: $259.90 ▼ -2.53 (-0.96%)MSFT: $540.03 ▲ 4.96 (0.93%)NVDA: $226.58 ▼ -2.70 (-1.18%)CIEN: $403.01 ▼ -46.76 (-10.40%)DDOG: $288.28 ▼ -4.98 (-1.70%)SNPS: $503.23 ▼ -6.77 (-1.33%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

TELA Bio, Inc.

TELA - NASDAQ

Identifiants & Marche

Ticker TELA
ISIN US8723811084
CIK 0001561921
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.